大肠癌筛检与诊断：全球市场

全球大肠癌筛检和诊断市场规模预计将从 2024 年的 400 亿美元增长到 2029 年的 461 亿美元，预测期内（2024-2029 年）的复合年增长率为 2.9%。

预计北美市场将从 2024 年的 244 亿美元成长到 2029 年的 287 亿美元，预测期内的复合年增长率为 3.3%。预计亚太市场规模将从 2024 年的 55 亿美元成长到 2029 年的 64 亿美元，复合年增长率为 3.1%。

本报告研究了全球结直肠癌筛检和诊断市场，并提供了市场的全面概述、市场影响因素和市场机会的分析、法律制度、新兴技术和技术发展的趋势、市场规模的趋势和预测、各个细分市场和地区的详细分析、竞争格局以及主要企业的概况。

目录

第一章执行摘要

• 市场展望
• 研究范围
• 市场分析

第二章 市场概况

• 疾病领域概述
• 大肠癌分期
• 第 0 阶段
• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段
• 病因
• 遗传因素
• 环境因素
• 病理生理
• 种系突变
• 零星突变
• 转移
• 临床意义
• 风险因素
• 遗传症候群
• 林奇症候群（HNPCC）
• 家族性腺瘤息肉症（FAP）
• 诊断
• 预后
• 结肠癌的类型
• 大肠直肠腺癌
• 胃肠道基质肿瘤（GIST）
• 类癌肿瘤
• Turcot 症候群
• Peutz-Jeghers 症候群 (PJS)
• 遗传性直肠癌（FCC）
• 幼年性息肉症候群 (JPS)
• 林奇症候群（遗传性非息肉性大肠直肠癌）
• MUTYH 相关息肉症 (MAP)
• 市场定义
• 纳入与排除标准
• 纳入标准
• 排除标准
• 市场概况
• 前进的道路
• 全球大肠直肠癌发生率
• 产业展望：法规结构
• 赎回情况
• 大肠镜检查及乙状结肠镜检查
• 粪便 DNA 检测
• 粪便免疫化学检查(FIT)
• 大便潜血试验(FOBT)
• 血液检测/生物标记检测
• 产品平臺
• 大肠直肠癌筛检和诊断检测的比较
• 大肠镜检查
• 乙状结肠镜检查
• 粪便免疫化学检查(FIT)
• 癒创木脂大便潜血试验(gFOBT)
• 粪便 DNA 检测

第三章 市场动态

• 市场动态概览
• 市场驱动因素
• 结肠癌发生率增加
• 经济负担加重
• 基因组学和分子诊断学的进展
• 非侵入性大肠癌筛检需求不断增长
• 早期癌症检测需求日益增长，以降低治疗成本
• 市场限制
• 非侵入性测试的敏感度有限
• 样本收集挑战
• 严格的规定
• 市场机会
• 在全球扩大大肠直肠癌筛检
• 新兴经济体潜力大

第四章 新兴科技与发展

• 大肠直肠癌筛检的多模态方法
• 家庭结肠癌检测套组的开发
• 肠道微生物群在结肠癌诊断上的新用途
• 引入人工智慧
• 数位健康干预
• 多种癌症检测 (MCD) 试验
• 自推进式大肠镜的开发
• Aer-O-Scope 大肠镜
• 冕铬矿

第五章市场区隔分析

• 主要市场趋势
• 细分市场
• 全球大肠直肠癌筛检和诊断测试服务市场
• 按测试类型进行的市场分析
• 大肠镜检查/乙状结肠镜检查
• 粪便 DNA 检测
• 市场规模及预测
• 血液检测/生物标记检测
• 大便潜血试验(FOBT)
• 粪便免疫化学检查(FIT)
• 最终用户的市场分析
• 医院和诊所
• 诊断实验室
• 门诊中心
• 居家照护
• 地理分布
• 市场分析：按地区
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第六章 竞争讯息

• 竞争格局
• 伙伴关係与合作
• 获得
• 业务扩展
• 资金和津贴
• 产品核准、上市和扩张
• 监管和法律活动
• 医疗保险和保险范围

7. 大肠直肠癌筛检和诊断检测服务市场永续性

• 永续性
• BCC的结语

第 8 章 附录

• 调查方法
• 来源
• 简称
• 公司简介
• DANAHER CORP.
• DIACARTA
• EIKEN CHEMICAL CO. LTD.
• EXACT SCIENCES CORP.
• FREENOME HOLDINGS INC.
• FUJIFILM HOLDINGS CORP.
• GI-VIEW
• GUARDANT HEALTH
• HANGZHOU NOVAHEALTH TECHNOLOGY CO. LTD.
• LABORATORY CORPORATION OF AMERICA HOLDINGS
• LEPU MEDICAL TECHNOLOGY (BEIJING) CO. LTD.
• MAINZ BIOMED NV
• NOVIGENIX SA
• OLYMPUS CORP.
• QUEST DIAGNOSTICS INC.
• QUIDELORTHO CORP.

The global market for colorectal cancer screening and diagnostic testing services is estimated to increase from $40.0 billion in 2024 to reach $46.1 billion by 2029, at a compound annual growth rate (CAGR) of 2.9% from 2024 through 2029.

The North American market for colorectal cancer screening and diagnostic testing services is estimated to increase from $24.4 billion in 2024 to reach $28.7 billion by 2029, at a CAGR of 3.3% from 2024 through 2029.

The Asia-Pacific market for colorectal cancer screening and diagnostic testing services is estimated to increase from $5.5 billion in 2024 to reach $6.4 billion by 2029, at a CAGR of 3.1% from 2024 through 2029.

Report Scope

This report summarizes the colorectal cancer screening and diagnostic testing service market, including a market snapshot and company profiles of leading product manufacturers/service providers. It provides a comprehensive market breakdown with in-depth information regarding each segment. The overview section of the report describes market trends and dynamics, including drivers, challenges, and opportunities. It provides information on emerging technologies and developments in the industry. The report also analyzes critical market players' financials, product portfolios, and recent activities.

BCC Research analyzed and made projections of each market and its applications, along with forecasts for the next five years. The report also features profiles of leading product manufacturers/service providers in the colorectal cancer screening and diagnostic testing service industry, including Fujifilm Holdings Corporation, Olympus Corporation, Exact Sciences Corporation, Danaher Corporation, Guardant Health, New Horizon Health, and Quest Diagnostics.

The market is segmented by geographical region into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further segregated:

• North America: The U.S., Canada, and Mexico.
• Europe: Germany, the U.K., France, Italy, Spain, and the Rest of Europe.
• Asia-Pacific: China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific.

Data for market estimates have been provided for 2021 and 2022 as the historical years and 2023 as the base year, with the forecast through 2029.

Report Includes

• 37 data tables and 71 additional tables
• Analyses of trends in the global market for colorectal cancer screening and diagnostics, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Estimates and forecasts of the market size by type, end user and geographic region
• Discussion of emerging technologies and developments, and the macroeconomic factors affecting the market
• Coverage of stages, etiology, pathophysiology, and risk factors of colorectal cancer, and discussion on its diagnosis, regulatory framework and reimbursement scenarios
• Information on product pipeline, approvals, launches and expansions and funding and grants in the medical industry
• Review of patent data and other new developments
• Discussion of ESG challenges and practices of the industry
• Assessment of the competitive landscape, including the market shares of leading companies, their product portfolios and financial overviews
• Information on recent mergers and acquisitions, expansions, collaborations, investments, and divestments
• Company profiles of major players within the industry, including Fujifilm Holdings Corp., Olympus Corp., Exact Sciences Corp., Danaher Corp., and Guardant Health

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Insights

Chapter 2 Market Overview

• Disease Area Overview
• Stages of Colorectal Cancer
• Stage 0
• Stage I
• Stage II
• Stage III
• Stage IV
• Etiology
• Genetic Factors
• Environmental Factors
• Pathophysiology
• Germline Mutations
• Sporadic Mutations
• Metastasis
• Clinical Implications
• Risk Factors
• Inherited Syndromes
• Lynch Syndrome (HNPCC)
• Familial Adenomatous Polyposis (FAP)
• Diagnosis
• Prognosis
• Types of Colorectal Cancer
• Colorectal Adenocarcinoma
• Gastrointestinal Stromal Tumors (GISTs)
• Carcinoids
• Turcot Syndrome
• Peutz-Jeghers Syndrome (PJS)
• Familial Colorectal Cancer (FCC)
• Juvenile Polyposis Syndrome (JPS)
• Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer)
• MUTYH-Associated Polyposis (MAP)
• Market Definition
• Inclusion and Exclusion Criteria
• Inclusion Criteria
• Exclusion Criteria
• Market Introduction
• The Road Ahead
• Global Prevalence of Colorectal Cancer
• Industry Outlook: Regulatory Framework
• Regulatory Framework in the U.S.
• Regulatory Framework in Europe
• Regulatory Framework in the Asia-Pacific Region
• Regulatory Landscape in Latin America
• Reimbursement Scenarios
• Colonoscopy and Sigmoidoscopy Tests
• Stool DNA Test
• Fecal Immunochemical Tests (FIT)
• Fecal Occult Blood Tests (FOBT)
• Blood-based/Biomarker Tests
• Product Pipeline
• Comparison of Colorectal Cancer Screening and Diagnostic Tests
• Colonoscopy Tests
• Sigmoidoscopy Tests
• Fecal Immunochemical Tests (FIT)
• Guaiac Fecal Occult Blood Tests (gFOBT)
• Stool DNA Tests

Chapter 3 Market Dynamics

• Market Dynamics Snapshot
• Market Drivers
• Increasing Incidence of Colorectal Cancer
• Growing Financial Burden
• Advances in Genomics and Molecular Diagnostics
• Rise in Demand for Non-Invasive Colorectal Cancer Screening
• Growing Need for Early Cancer Detection to Lower Treatment Costs
• Market Restraints
• Limited Sensitivity of Non-Invasive Testing Methods
• Sample Collection Challenges
• Stringent Regulations
• Market Opportunities
• Global Expansion of Colorectal Cancer Screening Programs
• Emerging Economies Proposing Significant Untapped Potential

Chapter 4 Emerging Technologies and Developments

• Introduction
• Multimodal Approaches to Colorectal Cancer Screening
• Development of At-Home Colorectal Cancer Screening Kits
• Emerging Use of Gut Microbiota in Colorectal Cancer Diagnosis
• Adoption of Artificial Intelligence (AI)
• Digital Health Interventions
• Multicancer Detection (MCD) Assays
• Development of Self-Propelled Colonoscopes
• Aer-O-Scope Colonoscope
• ColonoSight

Chapter 5 Market Segmentation Analysis

• Key Market Trends
• Segmentation Breakdown
• Global Market for Colorectal Cancer Screening and Diagnostic Testing Services
• Market Analysis by Test Type
• Colonoscopy and Sigmoidoscopy Tests
• Stool DNA Tests
• Market Size and Forecast
• Blood-Based/Biomarker Tests
• Fecal Occult Blood Tests (FOBT)
• Fecal Immunochemical Tests (FIT)
• Market Analysis by End User
• Hospitals and Clinics
• Diagnostic Laboratories
• Ambulatory Centers
• At-home Care
• Geographic Breakdown
• Market Analysis by Region
• North America
• Europe
• Asia-Pacific Region
• Rest of the World

Chapter 6 Competitive Intelligence

• Competitive Landscape
• Partnerships and Collaborations
• Acquisitions
• Business Expansions
• Funding and Grants
• Product Approvals, Launches and Expansions
• Regulatory and Legal Activities
• Medicare and Insurance Coverage

Chapter 7 Sustainability in the Colorectal Cancer Screening and Diagnostic Testing Service Market

• Introduction
• Sustainability
• Concluding Remarks from BCC

Chapter 8 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• DANAHER CORP.
• DIACARTA
• EIKEN CHEMICAL CO. LTD.
• EXACT SCIENCES CORP.
• FREENOME HOLDINGS INC.
• FUJIFILM HOLDINGS CORP.
• GI-VIEW
• GUARDANT HEALTH
• HANGZHOU NOVAHEALTH TECHNOLOGY CO. LTD.
• LABORATORY CORPORATION OF AMERICA HOLDINGS
• LEPU MEDICAL TECHNOLOGY (BEIJING) CO. LTD.
• MAINZ BIOMED N.V.
• NOVIGENIX SA
• OLYMPUS CORP.
• QUEST DIAGNOSTICS INC.
• QUIDELORTHO CORP.

List of Tables

• Summary Table : Global Market for Colorectal Cancer Screening and Diagnostic Testing Services, by Region, Through 2029
• Table 1 : Stage II Substages of Colorectal Cancer
• Table 2 : Stage III Substages of Colorectal Cancer
• Table 3 : Stage IV Substages of Colorectal Cancer
• Table 4 : Regulatory Landscape for Different Parameters for Key Countries
• Table 5 : Colonoscopy and Sigmoidoscopy Test Reimbursements, by Country, 2024
• Table 6 : Stool DNA Test Reimbursements, by Country, 2024
• Table 7 : Fecal Immunochemical Test Reimbursements, by Country, 2024
• Table 8 : Fecal Occult Blood Test Reimbursements, by Country, 2024
• Table 9 : Blood-based/Biomarker Test Reimbursements, by Country, 2024
• Table 10 : Cancer Screening and Diagnostic Product Pipeline, 2024
• Table 11 : Characteristics of CRC Screening Tests Currently Available in the U.S., 2024
• Table 12 : Characteristics of Recommended Colorectal Cancer Screening Tests, 2024
• Table 13 : Countries with Highest Colorectal Cancer Incidence and Rates, 2022
• Table 14 : Successful Colorectal Cancer Screening Initiatives, 2004-2011
• Table 15 : Examples of Product Launches and Approval in the Asia-Pacific Region, 2022
• Table 16 : Global Market for Colorectal Cancer Screening and Diagnostic Testing Services, Through 2029
• Table 17 : Global Market for Colorectal Cancer Screening and Diagnostic Testing Services, by Test Type, Through 2029
• Table 18 : Global Market for Colonoscopy and Sigmoidoscopy Tests, by Region, Through 2029
• Table 19 : Global Market for Stool DNA Tests, by Region, Through 2029
• Table 20 : Global Market for Blood-Based/Biomarker Tests, by Region, Through 2029
• Table 21 : Global Market for Fecal Occult Blood Tests (FOBT), by Region, Through 2029
• Table 22 : Global Market for Fecal Immunochemical Tests (FIT), by Region, Through 2029
• Table 23 : Global Market for Colorectal Cancer Screening and Diagnostic Testing Services, by End User, Through 2029
• Table 24 : Global Market for Hospitals and Clinics in Colorectal Cancer Screening and Diagnostic Testing Services, by Region, Through 2029
• Table 25 : Global Market for Diagnostic Laboratories in Colorectal Cancer Screening and Diagnostic Testing Services, by Region, Through 2029
• Table 26 : Global Market for Ambulatory Centers in Colorectal Cancer Screening and Diagnostic Testing Services, by Region, Through 2029
• Table 27 : Global Market for At-home Care in Colorectal Cancer Screening and Diagnostic Testing Services, by Region, Through 2029
• Table 28 : Global Market for Colorectal Cancer Screening and Diagnostic Testing Services, by Region, Through 2029
• Table 29 : North American Market for Colorectal Cancer Screening and Diagnostic Testing Services, by Country, Through 2029
• Table 30 : North American Market for Colorectal Cancer Screening and Diagnostic Testing Services, by Test Type, Through 2029
• Table 31 : North American Market for Colorectal Cancer Screening and Diagnostic Testing Services, by End User, Through 2029
• Table 32 : European Market for Colorectal Cancer Screening and Diagnostic Testing Services, by Country, Through 2029
• Table 33 : European Market for Colorectal Cancer Screening and Diagnostic Testing Services, by Test Type, Through 2029
• Table 34 : European Market for Colorectal Cancer Screening and Diagnostic Testing Services, by End User, Through 2029
• Table 35 : Asia-Pacific Market for Colorectal Cancer Screening and Diagnostic Testing Services, by Country, Through 2029
• Table 36 : Asia-Pacific Market for Colorectal Cancer Screening and Diagnostic Testing Services, by Test Type, Through 2029
• Table 37 : Asia-Pacific Market for Colorectal Cancer Screening and Diagnostic Testing Services, by End User, Through 2029
• Table 38 : ROW Market for Colorectal Cancer Screening and Diagnostic Testing Services, by Test Type, Through 2029
• Table 39 : ROW Market for Colorectal Cancer Screening and Diagnostic Testing Services, by End User, Through 2029
• Table 40 : Top Products and Their Manufacturers in the Colorectal Cancer Screening and Diagnostic Testing Service Market, 2023
• Table 41 : Select Strategic Alliances in the Colorectal Cancer Screening and Diagnostic Testing Service Market, 2022-2024
• Table 42 : Select Acquisitions in the Colorectal Cancer Screening and Diagnostic Testing Service Market, 2022-2024
• Table 43 : Major Business Expansion Activities in the Colorectal Cancer Screening and Diagnostic Testing Service Market, 2022-2024
• Table 44 : Major Grants and Funding Activities in the Colorectal Cancer Screening and Diagnostic Testing Service Market, 2022-2024
• Table 45 : Major Product Approvals, Launches, and Expansions in the Colorectal Cancer Screening and Diagnostic Testing Service Market, 2022-2024
• Table 46 : Major Regulatory and Legal Activities in the Colorectal Cancer Screening and Diagnostic Testing Service Market, 2024
• Table 47 : Major Medicare and Insurance Coverage in the Colorectal Cancer Screening and Diagnostic Testing Service Market, 2022-2024
• Table 48 : Recent ESG Highlights from Select Testing Services Providing Companies
• Table 49 : ESG Rankings for a Few Service-Providing Companies, 2024
• Table 50 : ESG Rankings for Major Product Manufacturing Companies, 2024
• Table 51 : Information Sources for this Report
• Table 52 : Glossary of Terms Used in the Colorectal Cancer Screening and Diagnostic Testing Service Market
• Table 53 : Danaher Corp.: Company Snapshot
• Table 54 : Danaher Corp.: Financial Performance, FY 2022 and 2023
• Table 55 : Danaher Corp.: Product Portfolio
• Table 56 : Danaher Corp.: News/Key Developments, 2022
• Table 57 : DiaCarta: Company Snapshot
• Table 58 : DiaCarta: Product Portfolio
• Table 59 : DiaCarta: News/Key Developments, 2023
• Table 60 : Eiken Chemical Co. Ltd.: Company Snapshot
• Table 61 : Eiken Chemical Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 62 : Eiken Chemical Co. Ltd.: Product Portfolio
• Table 63 : Eiken Chemical Co. Ltd.: News/Key Developments, 2022
• Table 64 : Exact Sciences Corp.: Company Snapshot
• Table 65 : Exact Sciences Corp.: Financial Performance, FY 2022 and 2023
• Table 66 : Exact Sciences Corp.: Product Portfolio
• Table 67 : Exact Sciences Corp.: News/Key Developments, 2022-2024
• Table 68 : Freenome Holdings Inc.: Company Snapshot
• Table 69 : Freenome Holdings Inc.: News/ Key Developments, 2023 and 2024
• Table 70 : Fujifilm Holdings Corp.: Company Snapshot
• Table 71 : Fujifilm Holdings Corp.: Financial Performance, FY 2022 and 2023
• Table 72 : Fujifilm Holdings Corp.: Product Portfolio
• Table 73 : GI-View: Company Snapshot
• Table 74 : GI-View: Product Portfolio
• Table 75 : Guardant Health: Company Snapshot
• Table 76 : Guardant Health: Financial Performance, FY 2022 and 2023
• Table 77 : Guardant Health: Product Portfolio
• Table 78 : Guardant Health: News/Key Developments, 2024
• Table 79 : Hangzhou NovaHealth Technology Co. Ltd.: Company Snapshot
• Table 80 : Hangzhou NovaHealth Technology Co. Ltd.: Financial Performance, FY 2021 and 2022
• Table 81 : Hangzhou NovaHealth Technology Co. Ltd.: Product Portfolio
• Table 82 : Hangzhou NovaHealth Technology Co. Ltd.: News/Key Developments, 2022
• Table 83 : Laboratory Corporation of America Holdings: Company Snapshot
• Table 84 : Laboratory Corporation of America Holdings: Financial Performance, FY 2022 and 2023
• Table 85 : Laboratory Corporation of America Holdings: Product Portfolio
• Table 86 : Laboratory Corporation of America Holdings: News/Key Developments, 2024
• Table 87 : Lepu Medical Technology (Beijing) Co. Ltd.: Company Snapshot
• Table 88 : Lepu Medical Technology (Beijing) Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 89 : Lepu Medical Technology (Beijing) Co. Ltd.: Product Portfolio
• Table 90 : Mainz Biomed N.V.: Company Snapshot
• Table 91 : Mainz Biomed N.V.: Financial Performance, FY 2022 and 2023
• Table 92 : Mainz Biomed N.V.: Product Portfolio
• Table 93 : Mainz Biomed N.V.: News/Key Developments, 2023 and 2024
• Table 94 : Novigenix SA: Company Snapshot
• Table 95 : Novigenix SA: Product Portfolio
• Table 96 : Olympus Corp.: Company Snapshot
• Table 97 : Olympus Corp.: Financial Performance, FY 2022 and 2023
• Table 98 : Olympus Corp.: Product Portfolio
• Table 99 : Olympus Corp.: News/Key Developments, 2024
• Table 100 : Quest Diagnostics Inc.: Company Snapshot
• Table 101 : Quest Diagnostics Inc.: Financial Performance, FY 2022 and 2023
• Table 102 : Quest Diagnostics Inc.: Product Portfolio
• Table 103 : Quest Diagnostics Inc.: News/Key Developments, 2023
• Table 104 : QuidelOrtho Corp.: Company Snapshot
• Table 105 : QuidelOrtho Corp.: Financial Performance, FY 2022 and 2023
• Table 106 : QuidelOrtho Corp.: Product Portfolio
• Table 107 : QuidelOrtho Corp.: News/Key Developments, 2024

List of Figures

• Summary Figure : Global Market Shares of Colorectal Cancer Screening and Diagnostic Testing Services, by Region, 2023
• Figure 1 : Five-Year Survival Rates, by Colorectal Cancer Location
• Figure 2 : Market Dynamics of Colorectal Cancer Screening and Diagnostic Testing
• Figure 3 : Emerging Technologies in the Colorectal Cancer Screening and Diagnostic Testing Service Market
• Figure 4 : Global Market Shares of Colorectal Cancer Screening and Diagnostic Testing Services, by Test Type, 2023
• Figure 5 : Global Market for Colonoscopy and Sigmoidoscopy Tests, by Region, 2021-2029
• Figure 6 : Global Market for Stool DNA Tests, by Region, 2021-2029
• Figure 7 : Global Market for Blood Based/Biomarker Tests, by Region, 2021-2029
• Figure 8 : Global Market for Fecal Occult Blood Tests (FOBT), by Region, 2021-2029
• Figure 9 : Global Market for Fecal Immunochemical Tests (FIT), by Region, 2021-2029
• Figure 10 : Global Market Shares of Colorectal Cancer Screening and Diagnostic Testing Services, by Region, 2023
• Figure 11 : North American Market Shares of Colorectal Cancer Screening and Diagnostic Testing Services, by Country, 2023
• Figure 12 : U.S. Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 13 : Canadian Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 14 : Mexican Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 15 : European Market Shares of Colorectal Cancer Screening and Diagnostic Testing Services, by Country, 2023
• Figure 16 : German Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 17 : U.K. Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 18 : French Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 19 : Italian Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 20 : Spanish Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 21 : Rest of European Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 22 : Asia-Pacific Market Shares of Colorectal Cancer Screening and Diagnostic Testing Services, by Country, 2023
• Figure 23 : Chinese Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 24 : Japanese Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 25 : Indian Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 26 : South Korean Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 27 : Australian Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 28 : Rest of Asia-Pacific Market for Colorectal Cancer Screening and Diagnostic Testing Services, 2021-2029
• Figure 29 : Total Number of Key Developments and Strategies, January 2022-November 2024
• Figure 30 : Partnerships and Collaborations, January 2022-November 2024
• Figure 31 : Acquisitions, January 2022-November 2024
• Figure 32 : Business Expansions, January 2022-November 2024
• Figure 33 : Funding and Grants, January 2022-November 2024
• Figure 34 : Product Approvals, Launches and Expansions, January 2022-November 2024
• Figure 35 : Regulatory and Legal Activities, January 2022-November 2024
• Figure 36 : Medicare and Insurance Coverage, January 2022-November 2024
• Figure 37 : Snapshot of ESG Pillars
• Figure 38 : Danaher Corp.: Revenue Shares, by Business Unit, FY 2023
• Figure 39 : Danaher Corp.: Revenue Shares, by Country/Region, FY 2023
• Figure 40 : Eiken Chemical Co. Ltd.: Revenue Shares, by Product Type, FY 2023
• Figure 41 : Exact Sciences Corp.: Revenue Shares, by Business Unit, FY 2023
• Figure 42 : Exact Sciences Corp.: Revenue Shares, by Country/Region, FY 2023
• Figure 43 : Fujifilm Holdings Corp.: Revenue Shares, by Business Unit, FY 2023
• Figure 44 : Fujifilm Holdings Corp.: Revenue Shares, by Country/Region, FY 2023
• Figure 45 : Guardant Health: Revenue Shares, by Business Unit, FY 2023
• Figure 46 : Guardant Health: Revenue Shares, by Country/Region, FY 2023
• Figure 47 : Hangzhou NovaHealth Technology Co. Ltd.: Revenue Shares, by Business Unit, FY 2022
• Figure 48 : Hangzhou NovaHealth Technology Co. Ltd.: Revenue Shares, by Country/Region, FY 2022
• Figure 49 : Laboratory Corporation of America Holdings: Revenue Shares, by Business Unit, FY 2023
• Figure 50 : Laboratory Corporation of America Holdings: Revenue Shares, by Country/Region, FY 2023
• Figure 51 : Lepu Medical Technology (Beijing) Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
• Figure 52 : Olympus Corp.: Revenue Shares, by Business Unit, FY 2023
• Figure 53 : Olympus Corp.: Revenue Shares, by Country/Region, FY 2023
• Figure 54 : Quest Diagnostics Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 55 : QuidelOrtho Corp.: Revenue Shares, by Business Unit, FY 2023
• Figure 56 : QuidelOrtho Corp.: Revenue Shares, by Country/Region, FY 2023